Management of chronic obstructive pulmonary disease: Moving beyond the asthma algorithm

Journal of Allergy and Clinical Immunology

Volumn 124, Issue 5, 2009, Pages 873-880

  Gordon, Erin ^a   Lazarus, Stephen C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

2 agonists; airflow obstruction; anticholinergics; antioxidants; asthma; bronchodilators; Chronic obstructive pulmonary disease; home oxygen; immunization; inhaled corticosteroids; long acting bronchodilators; mucolytics; oral corticosteroids; pulmonary rehabilitation; smoking cessation

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; C REACTIVE PROTEIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DORNASE ALFA; FLUTICASONE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; INFLUENZA VACCINE; IPRATROPIUM BROMIDE; MUCOLYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PNEUMOCOCCUS VACCINE; PREDNISOLONE; ROFLUMILAST; SALMETEROL; STEROID; TIOTROPIUM BROMIDE; TRIAMCINOLONE;

ADRENAL SUPPRESSION; AIRWAY OBSTRUCTION; ASTHMA; BONE DENSITY; BRONCHITIS; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG MEGADOSE; EXERCISE; EXERCISE TOLERANCE; FRACTURE; GLUCOSE INTOLERANCE; HEALTH CARE PERSONNEL; HOSPITALIZATION; HUMAN; INFLUENZA VACCINATION; LOW DRUG DOSE; LUNG FUNCTION; MORTALITY; NONHUMAN; OPSONIZATION; OXIDATIVE STRESS; OXYGEN THERAPY; PATHOPHYSIOLOGY; PNEUMONIA; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY REHABILITATION; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SIGNAL TRANSDUCTION; SMOKING CESSATION;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-ANTAGONISTS; ALBUTEROL; ANDROSTADIENES; ANTIOXIDANTS; ASTHMA; BACTERIAL VACCINES; BRONCHODILATOR AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; VIRAL VACCINES;

EID: 71749083633     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.09.040     Document Type: Review

References (104)

1. Pauwels R.A., and Rabe K.F. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 364 (2004) 613-620
2. Willart M.A., and Lambrecht B.N. The danger within: endogenous danger signals, atopy and asthma. Clin Exp Allergy 39 (2009) 12-19
3. Eisner M.D., Balmes J., Katz P.P., Trupin L., Yelin E.H., and Blanc P.D. Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease. Environ Health 4 (2005) 7
4. Liu S., Zhou Y., Wang X., Wang D., Lu J., Zheng J., et al. Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural South China. Thorax 2007 (2007) 889-897
5. Adams N.P., Bestall J.B., and Jones P.W. Inhaled beclomethasone versus placebo for chronic asthma. Cochrane Database Syst Rev (2000) (4):CD002738
6. Willemse B.W., Postma D.S., Timens W., and ten Hacken N.H. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J 23 (2004) 464-476
7. Barnes P.J. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 118 (2008) 3546-3556
8. Haahtela T., Järvinen M., Kava T., Kiviranta K., Koskinen S., Lehtonen K., et al. Comparison of a β2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 325 (1991) 388-392
9. Haahtela T., Järvinen M., Kava T., Kiviranta K., Koskinen S., Lehtonen K., et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 331 (1994) 700-705
10. van Essen-Zandvliet E.E., Hughes M.D., Waalkens H.J., Duiverman E.J., Pocock S.J., and Kerrebijn K.F. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. Am Rev Respir Dis 146 (1992) 547-554
11. Kerstjens H.A., Brand P.L., Hughes M.D., Robinson N.J., Postma D.S., Sluiter H.J., et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group. N Engl J Med 327 (1992) 1413-1419
12. Juniper E.F., Kline P.A., Vanzielehgem M.A., Ramsdale E.H., O'Byrne P.M., and Hargreave F.E. Effect of long-term treatment with an inhaled corticosteroid on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 142 (1990) 832-836
13. Suissa S., Ernst P., Benayoun S., Baltzan M., and Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 343 (2000) 332-336
14. Pauwels R.A., Pedersen S., Busse W.W., Tan W.C., Chen Y.Z., Ohlsson S.V., et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 361 (2003) 1071-1076
15. Hattotuwa K.L., Gizycki M.J., Ansari T.W., Jeffery P.K., and Barnes N.C. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 165 (2002) 1592-1596
16. Verhoeven G.T., Hegmans J.P., Mulder P.G., Bogaard J.M., Hoogsteden H.C., and Prins J.B. Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thorax 57 (2002) 694-700
17. Llewellyn-Jones C.G., Harris T.A., and Stockley R.A. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Respir Crit Care Med 153 (1996) 616-621
18. Culpitt S.V., Maziak W., Loukidis S., Nightingale J.A., Matthews J.L., and Barnes P.J. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160 (1999) 1635-1639
19. Brightling C.E., McKenna S., Hargadon B., Birring S., Green R., Siva R., et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 60 (2005) 193-198
20. Thompson A.B., Mueller M.B., Heires A.J., Bohling T.L., Daughton D., Yancey S.W., et al. Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation. Am Rev Respir Dis 146 (1992) 389-395
21. Ozol D., Aysan T., Solak Z.A., Mogulkoc N., Veral A., and Sebik F. The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients. Respir Med 99 (2005) 1494-1500
22. Sin D.D., Lacy P., York E., and Man S.F. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170 (2004) 760-765
23. John M., Bosse S., Oltmanns U., Schumacher A., and Witt C. Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease. Respir Med 99 (2005) 1418-1424
24. Drummond M.B., Dasenbrook E.C., Pitz M.W., Murphy D.J., and Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 300 (2008) 2407-2416
25. Vestbo J., Sorensen T., Lange P., Brix A., Torre P., and Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 353 (1999) 1819-1823
26. Pauwels R.A., Lofdahl C.G., Laitinen L.A., Schouten J.P., Postma D.S., Pride N.B., et al. Long-term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 340 (1999) 1948-1953
27. Burge P.S., Calverley P.M., Jones P.W., Spencer S., Anderson J.A., and Maslen T.K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320 (2000) 1297-1303
28. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 343 (2000) 1902-1909
29. Yang I.A., Fong K.M., Sim E.H., Black P.N., and Lasserson T.J. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2007) (2):CD002991
30. Celli B.R., Thomas N.E., Anderson J.A., Ferguson G.T., Jenkins C.R., Jones P.W., et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 178 (2008) 332-338
31. Alsaeedi A., Sin D.D., and McAlister F.A. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 113 (2002) 59-65
32. Fabbri L., Pauwels R.A., and Hurd S.S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary updated 2003. COPD 1 (2004) 105-141 discussion 103-4
33. Celli B.R., and MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 (2004) 932-946
34. Decramer M., and Stas K.J. Corticosteroid-induced myopathy involving respiratory muscles in patients with chronic obstructive pulmonary disease or asthma. Am Rev Respir Dis 146 (1992) 800-802
35. Decramer M., Lacquet L.M., Fagard R., and Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 150 (1994) 11-16
36. Rice K.L., Rubins J.B., Lebahn F., Parenti C.M., Duane P.G., Kuskowski M., et al. Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial. Am J Respir Crit Care Med 162 (2000) 174-178
37. Renkema T.E., Schouten J.P., Koeter G.H., and Postma D.S. Effects of long-term treatment with corticosteroids in COPD. Chest 109 (1996) 1156-1162
38. Walters J.A., Walters E.H., and Wood-Baker R. Oral corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2005) (3):CD005374
39. Brightling C.E., Monteiro W., and Ward R. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 356 (2000) 1480-1485
40. Dorinsky P.M., Reisner C., Ferguson G.T., Menjoge S.S., Serby C.W., and Witek Jr. T.J. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 115 (1999) 966-971
41. Westby M., Benson M., and Gibson P. Anticholinergic agents for chronic asthma in adults. Cochrane Database Syst Rev (2004) (3):CD003269
42. van Schayck C.P., Folgering H., Harbers H., Maas K.L., and van Weel C. Effects of allergy and age on responses to salbutamol and ipratropium bromide in moderate asthma and chronic bronchitis. Thorax 46 (1991) 355-359
43. Appleton S., Jones T., Poole P., Pilotto L., Adams R., Lasserson T.J., et al. Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2006) (2):CD001387
44. Disse B., Speck G.A., Rominger K.L., Witek Jr. T.J., and Hammer R. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 64 (1999) 457-464
45. Barnes P.J. The pharmacological properties of tiotropium. Chest 117 suppl (2000) 63S-66
46. Vincken W., van Noord J.A., Greefhorst A.P., Bantje T.A., Kesten S., Korducki L., et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 19 (2002) 209-216
47. Casaburi R., Mahler D.A., Jones P.W., Wanner A., San P.G., ZuWallack R.L., et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19 (2002) 217-224
48. O'Donnell D.E., Fluge T., Gerken F., Hamilton A., Webb K., Aguilaniu B., et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 23 (2004) 832-840
49. Maltais F., Hamilton A., Marciniuk D., Hernandez P., Sciurba F.C., Richter K., et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 128 (2005) 1168-1178
50. Brusasco V., Hodder R., Miravitlles M., Korducki L., Towse L., and Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 58 (2003) 399-404
51. Niewoehner D.E., Rice K., Cote C., Paulson D., Cooper Jr. J.A., Korducki L., et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 143 (2005) 317-326
52. Barr R.G., Bourbeau J., Camargo C.A., and Ram F.S. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 61 (2006) 854-862
53. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S.S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359 (2008) 1543-1554
54. Sestini P., Renzoni E., Robinson S., Poole P., and Ram F.S. Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2002) (4):CD001495
55. Lazarus S.C., Boushey H.A., Fahy J.V., Chinchilli V.M., Lemanske R.F., Sorkness C.A., et al. Long-Acting β2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma. A randomized controlled trial. JAMA 285 (2001) 2583-2593
56. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics-2002. J Allergy Clin Immunol 110 suppl (2002) S141-S219
57. Nelson H.S., Weiss S.T., Bleecker E.R., Yancey S.W., Dorinsky P.M., and Group S.S. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129 (2006) 15-26
58. National Asthma Education and Prevention Program. Expert panel report 3 (EPR3): guidelines for diagnosis and management of asthma-summary report. J Allergy Clin Immunol 120 suppl (2007) S94-S138
59. Bateman E.D., Hurd S.S., Barnes P.J., Bousquet J., Drazen J.M., FitzGerald M., et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 31 (2008) 143-178
60. Appleton S., Poole P., Smith B., Veale A., Lasserson T.J., and Chan M.M. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2006) (3):CD001104
61. Nannini L.J., Cates C.J., Lasserson T.J., and Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2007) (4):CD006826
62. Calverley P.M.A., Anderson J.A., Celli B., Ferguson G.T., Jenkins C.R., Jones P.W., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007) 775-789
63. Poole P.J., and Black P.N. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2006) (3):CD001287
64. Boogaard R., Smit F., Schornagel R., Vaessen-Verberne A.A., Kouwenberg J.M., Hekkelaan M., et al. Recombinant human deoxyribonuclease for the treatment of acute asthma in children. Thorax 63 (2008) 141-146
65. Grandjean E.M., Berthet P., Ruffman R., and Leuenberger P. Efficacy of oral long-term N-acetylcysteine in bronchopulmonary disease: a meta-analysis of published double-blind placebo-controlled clinical trials. Clin Ther 22 (2000) 209-221
66. Stey C., Steurer J., Bachmann S., Medici T.C., and Tramer M.R. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 16 (2000) 253-262
67. Poole P.J., and Black P.N. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 322 (2001) 1271-1274
68. Decramer M., Rutten-van Molken M., Dekhuijzen P.N.R., Troosters T., van Herwaarden C., Pellegrino R., et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo controlled trial. Lancet 365 (2005) 1552-1560
69. Smith V.B., and Spina D. Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation. Curr Opin Investig Drugs 6 (2005) 1136-1141
70. Grootendorst D.C., Gauw S.A., Verhoosel R.M., Sterk P.J., Hospers J.J., Bredenbroker D., et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 62 (2007) 1081-1087
71. Rabe K.F., Bateman E.D., O'Donnell D., Witte S., Bredenbroker D., and Bethke T.D. Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 366 (2005) 563-571
72. Calverley P.M., Sanchez-Toril F., McIvor A., Teichmann P., Bredenbroeker D., and Fabbri L.M. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 176 (2007) 154-161
73. Fabbri L.M., Calverley P.M., Izquierdo-Alonso J.L., Bundschuh D.S., Brose M., Martinez F.J., et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 374 (2009) 695-703
74. Calverley P.M., Rabe K.F., Goehring U.M., Kristiansen S., Fabbri L.M., and Martinez F.J. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374 (2009) 685-694
75. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 93 (1980) 391-398
76. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1 (1981) 681-686
77. Gorecka D., Gorzelak K., Sliwinski P., Tobiasz M., and Zielinski J. Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia. Thorax 52 (1997) 674-679
78. Chaudhuri R., Livingston E., McMahon A.D., Lafferty J., Fraser I., Spears M., et al. Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am J Respir Crit Care Med 174 (2006) 127-133
79. Anthonisen N.R., Connett J.E., Kiley J.P., Altose M.D., Bailey W.C., Buist A.S., et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 272 (1994) 1497-1505
80. Anthonisen N.R., Skeans M.A., Wise R.A., Manfreda J., Kanner R.E., and Connett J.E. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 142 (2005) 233-239
81. Postma D.S., de Vries K., Koeter G.H., and Sluiter H.J. Independent influence of reversibility of air-flow obstruction and nonspecific hyperreactivity on the long-term course of lung function in chronic air-flow obstruction. Am Rev Respir Dis 134 (1986) 276-280
82. Kanner R.E., Renzetti Jr. A.D., Stanish W.M., Barkman Jr. H.W., and Klauber M.R. Predictors of survival in subjects with chronic airflow limitation. Am J Med 74 (1983) 249-255
83. Postma D.S., Gimeno F., van der Weele L.T., and Sluiter H.J. Assessment of ventilatory variables in survival prediction of patients with chronic airflow obstruction: the importance of reversibility. Eur J Respir Dis 67 (1985) 360-368
84. Siroux V., Pin I., Oryszczyn M.P., Le Moual N., and Kauffmann F. Relationships of active smoking to asthma and asthma severity in the EGEA study. Epidemiological study on the Genetics and Environment of Asthma. Eur Respir J 15 (2000) 470-477
85. Althuis M.D., Sexton M., and Prybylski D. Cigarette smoking and asthma symptom severity among adult asthmatics. J Asthma 36 (1999) 257-264
86. Apostol G.G., Jacobs Jr. D.R., Tsai A.W., Crow R.S., Williams O.D., Townsend M.C., et al. Early life factors contribute to the decrease in lung function between ages 18 and 40: the Coronary Artery Risk Development in Young Adults study. Am J Respir Crit Care Med 166 (2002) 166-172
87. Lange P., Parner J., Vestbo J., Schnohr P., and Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 339 (1998) 1194-1200
88. Marquette C.H., Saulnier F., Leroy O., Wallaert B., Chopin C., Demarcq J.M., et al. Long-term prognosis of near-fatal asthma. A 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for a near-fatal attack of asthma. Am Rev Respir Dis 146 (1992) 76-81
89. Lazarus S.C., Chinchilli V.M., Rollings N.J., Boushey H.A., Cherniack R., Craig T.J., et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 175 (2007) 783-790
90. Gonzales D., Rennard S.I., Nides M., Oncken C., Azoulay S., Billing C.B., et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296 (2006) 47-55
91. Jorenby D.E., Hays J.T., Rigotti N.A., Azoulay S., Watsky E.J., Williams K.E., et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296 (2006) 56-63
92. Casaburi R., and ZuWallack R. Pulmonary rehabilitation for management of chronic obstructive pulmonary disease. N Engl J Med 360 (2009) 1329-1335
93. Ries A.L., Bauldoff G.S., Carlin B.W., Casaburi R., Emery C.F., Mahler D.A., et al. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest 131 suppl (2007) 4S-42
94. Lacasse Y., Goldstein R., Lasserson T.J., and Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2006) (4):CD003793
95. Ram F.S., Robinson S.M., Black P.N., and Picot J. Physical training for asthma. Cochrane Database Syst Rev (2005) (4):CD001116
96. Nichol K.L., Margolis K.L., Wuorenma J., and Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 331 (1994) 778-784
97. Poole P.J., Chacko E., Wood-Baker R.W., and Cates C.J. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2006) (1):CD002733
98. The ALA Asthma Clinical Research Centers. The safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med 345 (2001) 1529-1536
99. Cates C.J., Jefferson T.O., and Rowe B.H. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev (2008) (2):CD000364
100. Bueving H.J., Bernsen R.M., de Jongste J.C., van Suijlekom-Smit L.W., Rimmelzwaan G.F., Osterhaus A.D., et al. Influenza vaccination in children with asthma: randomized double-blind placebo-controlled trial. Am J Respir Crit Care Med 169 (2004) 488-493
101. Talbot T.R., Hartert T.V., Mitchel E., Halasa N.B., Arbogast P.G., Poehling K.A., et al. Asthma as a risk factor for invasive pneumococcal disease. N Engl J Med 352 (2005) 2082-2090
102. Juhn Y.J., Kita H., Yawn B.P., Boyle T.G., Yoo K.H., McGree M.E., et al. Increased risk of severe pneumococcal disease in patients with asthma. J Allergy Clin Immunol 122 (2008) 719-723
103. Centers for Disease Control and Prevention. Recommended adult immunization schedule-United States 2009. MMWR 57 53 (2009)
104. Dransfield M.T., Nahm M.H., Han M.K., Harnden S., Criner G.J., Martinez F.J., et al. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 180 (2009) 499-505